Table 1.
Baseline characteristics.
| Cohort 1 (N = 7) | Cohort 2 (N = 29) | Overall (N = 36) | |
|---|---|---|---|
| Age, median (range) | 79 (59-90) | 72 (54-88) | 73 (54-90) |
| Male, N (%) | 5 (71.4%) | 22 (75.9%) | 27 (75%) |
| White, N (%) | 5 (71.4%) | 27 (93.1%) | 32 (88.9%) |
| Black, N (%) | 2 (28.6%) | 2 (6.9%) | 4 (11.1%) |
| Non-Hispanic, N (%) | 7 (100%) | 28 (96.6%) | 35 (97.2%) |
| Karnofsky performance status, median (range) | 60 (60-70) | 80 (60-100) | 80 (60-100) |
| Calculated creatinine clearance, median (range) | 36.03 (10.54-60) | 51.3 (22-96) | 50.35 (10.54-96) |
Of the 36 patients enrolled, the majority (75%, N = 27) were men. Seven patients with both impaired renal function and poor performance status were assigned to EVE in cohort 1. Twenty-nine patients with either impaired renal function or poor performance status were assigned to EVP in cohort 2. The median Karnofsky performance status (60% vs 80%, P < .001) and calculated creatinine clearance (36.03 vs 51.3 mL/minute, P = .12) were both numerically lower in cohort 1 compared with cohort 2.